References
- Kirkali Z, Tuzel E. Systemic therapy of kidney cancer: tyrosine kinase inhibitors, angiogenesis or IL-2? Future Oncol.5, 871–888 (2009).
- Sternberg CN, Szczylik C, Lee E et al. A randomized, double-blind Phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol.27(Suppl. 15), (2009) (Abstract 5021).
- Singh H, Milner CS, Aquilar Hernandez MM et al. Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases. Cell. Signal.21(8), 1346–1350 (2009).
- Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev. Anticancer Ther.9(6), 785–793 (2009).
- Kirkali Z. Will we be able to “cure” metastatic renal cell carcinoma like we cure testicular tumors? Eur. Urol.54, 712–714 (2008).